{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:20:40Z","timestamp":1790176840178,"version":"4.1.0"},"reference-count":85,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T00:00:00Z","timestamp":1538438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Women's Dermatology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ijwd.2018.09.004","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T15:33:03Z","timestamp":1542727983000},"page":"30-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["New oral and topical approaches for the treatment of melasma"],"prefix":"10.1097","volume":"5","author":[{"given":"P.E.","family":"Grimes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nashawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.ijwd.2018.09.004_bb9000","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/CCID.S20543","article-title":"Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial","volume":"4","author":"Adalatkhah","year":"2011","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0005","first-page":"4219","article-title":"The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: A randomized clinical trial. Drug design, development and therapy","volume":"9","author":"Adalatkhah","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"10.1016\/j.ijwd.2018.09.004_bb0010","first-page":"14","article-title":"Topical vitamin C and the skin: Mechanisms of action and clinical applications","volume":"10","author":"Al-Niaimi","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0015","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1365-2133.2003.05419.x","article-title":"Development and validation of a health-related quality of life instrument for women with melasma","volume":"149","author":"Balkrishnan","year":"2003","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/jocd.12152","article-title":"Comparison of therapeutic effects of liposomal tranexamic acid and conventional hydroquinone on melasma","volume":"14","author":"Banihashemi","year":"2015","journal-title":"J Cosmet Dermatol"},{"issue":"15-16","key":"10.1016\/j.ijwd.2018.09.004_bb0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.drudis.2013.02.003","article-title":"Cysteamine: An old drug with new potential","volume":"18","author":"Besouw","year":"2013","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/j.ijwd.2018.09.004_bb0030","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4103\/0019-5154.169122","article-title":"Exogenous ochronosis","volume":"60","author":"Bhattar","year":"2015","journal-title":"Indian J Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1399-3011.1985.tb02155.x","article-title":"The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor from soybeans","volume":"25","author":"Birk","year":"1985","journal-title":"Int J Pept Protein Res"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0040","first-page":"8","article-title":"Topical niacinamide and barrier enhancement","volume":"70","author":"Bissett","year":"2002","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.ijwd.2018.09.004_bb0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaad.2014.08.023","article-title":"Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: A prospective randomized comparative trial","volume":"72","author":"Boukari","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2018.09.004_bb0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/phpp.12086","article-title":"Visible-light photoprotection in melasma","volume":"30","author":"Castanedo-Cazares","year":"2014","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0055","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10408449991349221","article-title":"The toxicology of hydroquinone-relevance to occupational and environmental exposure","volume":"29","author":"De Caprio","year":"1999","journal-title":"Crit Rev Toxicol"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2017.09.053","article-title":"Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate to severe melasma","volume":"78","author":"Del Rosario","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2018.09.004_bb0065","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4103\/0019-5154.113940","article-title":"Kojic acid vis-a-vis its combinations with hydroquinone and betamethasone valerate in melasma: A randomized, single blind, comparative study of efficacy and safety","volume":"58","author":"Deo","year":"2013","journal-title":"Indian J Dermatol"},{"issue":"8","key":"10.1016\/j.ijwd.2018.09.004_bb0070","first-page":"753","article-title":"Topical tranexamic acid as a promising treatment for melasma","volume":"19","author":"Ebrahimi","year":"2014","journal-title":"J Res Med Sci"},{"issue":"5","key":"10.1016\/j.ijwd.2018.09.004_bb0075","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/pcmr.12273","article-title":"Differences in visible light-induced pigmentation according to wavelengths: A clinical and histological study in comparison with UVB exposure","volume":"27","author":"Duteil","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"10.1016\/j.ijwd.2018.09.004_bb0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/phpp.12325","article-title":"A method to assess the protective efficacy of sunscreens against visible light-induced pigmentation","volume":"33","author":"Duteil","year":"2017","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/2349-5847.196295","article-title":"Tranexamic acid: An emerging depigmenting agent","volume":"3","author":"George","year":"2016","journal-title":"Pigment Int"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0090","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jsps.2018.02.019","article-title":"The release studies of undecylenoyl phenylalanine through cellulose based membranes","volume":"26","author":"Glowka","year":"2018","journal-title":"Saudi Pharm J"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0095","first-page":"14","article-title":"Double-blind, placebo-controlled trial to evaluate the effectiveness of Polypodium leucotomos extract in the treatment of melasma in Asian skin: A pilot study","volume":"11","author":"Goh","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"issue":"12","key":"10.1016\/j.ijwd.2018.09.004_bb0100","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/archderm.1995.01690240119022","article-title":"Melasma: Etiologic and therapeutic considerations","volume":"131","author":"Grimes","year":"1995","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.sder.2009.04.001","article-title":"Management of hyperpigmentation in darker racial ethnic groups","volume":"28","author":"Grimes","year":"2009","journal-title":"Semin Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.dad.0000154419.18653.2e","article-title":"Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma","volume":"27","author":"Grimes","year":"2005","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"10.1016\/j.ijwd.2018.09.004_bb0115","first-page":"388","article-title":"Incidence of common dermatoes in a predominantly black dermatologic practice","volume":"32","author":"Halder","year":"1983","journal-title":"Cutis"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0120","first-page":"30","article-title":"The role of topical and oral melatonin in management of melasma patients","volume":"8","author":"Hamadi","year":"2009","journal-title":"J Arab Univ Basic Appl Sci"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ijd.12999","article-title":"An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women","volume":"55","author":"Handog","year":"2016","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2018.09.004_bb0130","first-page":"641","article-title":"The efficacy and safety of azelaic acid 15% foam in the treatment of facial acne vulgaris","volume":"17","author":"Hashim","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2018.09.004_bb9100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1346-8138.2010.00787.x","article-title":"Efficacy and safety of liposome\u2010encapsulated 4\u2010n\u2010butylresorcinol 0.1% cream for the treatment of melasma: A randomized controlled split\u2010face trial","volume":"37","author":"Huh","year":"2010","journal-title":"J Dermatol."},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1590\/abd1806-4841.20152771","article-title":"Melasma and assessment of the quality of life in Brazilian women","volume":"90","author":"Ikino","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2013.07.044","article-title":"Systematic review of randomized controlled trials on interventions for melasma","volume":"70","author":"Jutley","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0145","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S0151-9638(12)70117-5","article-title":"Melasma and aspects of pigmentary disorders in Asians","volume":"139","author":"Kang","year":"2012","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ijwd.2018.09.004_bb0150","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1365-2133.2006.07179.x","article-title":"The dermal stem and c-Kit are overexpressed in melasma","volume":"154","author":"Kang","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0155","first-page":"10","article-title":"The mechanism of action of topical retinoids","volume":"75","author":"Kang","year":"2005","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0160","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.0007-0963.2001.04556.x","article-title":"Melasma: Histopathological characteristics in 56 Korean patients","volume":"146","author":"Kang","year":"2002","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2018.09.004_bb0165","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000088509","article-title":"Topical methimazole as a new treatment for postinflammatory hyperpigmentation: Report of the first case","volume":"211","author":"Kasraee","year":"2005","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.ijwd.2018.09.004_bb0170","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000148222","article-title":"Safety of topical methimazole for the treatment of melasma: Transdermal absorption, the effect on thyroid function and cutaneous adverse effects","volume":"21","author":"Kasraee","year":"2008","journal-title":"Skin Pharmacol Physiol"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb9200","first-page":"179","article-title":"Mequinol 2%\/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature","volume":"81","author":"Keeling","year":"2008","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdermsci.2007.01.009","article-title":"The vascular characteristics of melasma","volume":"46","author":"Kim","year":"2007","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb9300","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5021\/ad.2015.27.3.250","article-title":"Tranexamic acid diminishes laser-induced melanogenesis","volume":"27","author":"Kim","year":"2015","journal-title":"Ann Dermatol"},{"issue":"6-7","key":"10.1016\/j.ijwd.2018.09.004_bb9400","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2340\/00015555-2668","article-title":"Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review","volume":"97","author":"Kim","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.ijwd.2018.09.004_bb0180","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/ced.12835","article-title":"Efficacy and possible mechanisms of topical tranexamic acid in melasma","volume":"41","author":"Kim","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0185","doi-asserted-by":"crossref","first-page":"95245","DOI":"10.1155\/2012\/952452","article-title":"Depigmenting effect of Kojic acid esters in hyperpigmented B16F1 melanoma cells","volume":"2012","author":"Lajis","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"6","key":"10.1016\/j.ijwd.2018.09.004_bb0190","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1468-3083.2007.02185.x","article-title":"Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women","volume":"21","author":"Lakhdar","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ijwd.2018.09.004_bb0195","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/pcmr.12404","article-title":"Recent progress in melasma pathogenesis","volume":"28","author":"Lee","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.ijwd.2018.09.004_bb0200","first-page":"36","article-title":"Melasma","volume":"152","author":"Lee","year":"2017","journal-title":"G Ital Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2016.03.001","article-title":"Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis","volume":"75","author":"Lee","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.ijwd.2018.09.004_bb0210","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/jid.2010.95","article-title":"Impact of long-wavelength UVA and visible light on melanocompetent skin","volume":"130","author":"Mahmoud","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.ijwd.2018.09.004_bb0215","first-page":"1562","article-title":"Development and clinical assessment of a comprehensive product for pigmentation control in multiple ethnic populations","volume":"15","author":"Makino","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2018.09.004_bb0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjd.13424","article-title":"Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: A randomized double-blind placebo-controlled trial","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.ijwd.2018.09.004_bb0225","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamadermatol.2013.4294","article-title":"A randomized double-blind placebo controlled study evaluating the effectiveness and tolerability of oral Polypodium leucotomos in patients with melasma","volume":"149","author":"Martin","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0230","first-page":"169","article-title":"Rationale for the use of topical corticosteroids in melasma","volume":"3","author":"Menter","year":"2004","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0235","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-4632.2004.02470.x","article-title":"Prevalence and awareness of melasma during pregnancy","volume":"45","author":"Moin","year":"2006","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/0019-5154.108070","article-title":"A comparative study of the efficacy of 4% hydroquinone vs 0.75% Kojic acid cream in the treatment of facial melasma","volume":"58","author":"Monteiro","year":"2013","journal-title":"Indian J Dermatol"},{"issue":"8","key":"10.1016\/j.ijwd.2018.09.004_bb0245","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-3083.2012.04464.x","article-title":"Effect of tranexamic acid on melasma: A clinical trial with histological evaluation","volume":"27","author":"Na","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0250","doi-asserted-by":"crossref","first-page":"379173","DOI":"10.1155\/2011\/379173","article-title":"A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma","volume":"2011","author":"Navarrete-Sol\u00eds","year":"2011","journal-title":"Dermatol Res Pract"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0255","first-page":"13","article-title":"Polypodium leucotomos as an adjunct treatment of pigmentary disorders","volume":"7","author":"Nestor","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0260","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00403-018-1850-8","article-title":"Glucosamine abrogates the stem cell factor+endothelin-1-induced stimulation of melanogenesis via a deficiency in MITF expression due to the proteolytic degradation of CREB in human melanocytes","volume":"310","author":"Niwano","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0265","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1468-3083.2006.01670.x","article-title":"The safety of hydroquinone","volume":"20","author":"Nordlund","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0270","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jsps.2018.02.019","article-title":"Release studies of undecylenoyl phenylalanine from topical formulations","volume":"26","author":"Olejnik","year":"2018","journal-title":"Saudi Pharm J"},{"issue":"4","key":"10.1016\/j.ijwd.2018.09.004_bb0275","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1523-1747.2001.01291.x","article-title":"An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway","volume":"116","author":"Paine","year":"2001","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2018.09.004_bb0280","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/pcmr.12684","article-title":"Melasma, a photoaging disorder","volume":"31","author":"Passeron","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.ijwd.2018.09.004_bb0285","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/09546630601028778","article-title":"Melasma and its impact on health-related quality of life in Hispanic women","volume":"18","author":"Pawaskar","year":"2007","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0290","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40257-017-0263-3","article-title":"Tranexamic acid in the treatment of melasma: A review of the literature","volume":"18","author":"Perper","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0295","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.det.2007.04.012","article-title":"New and experimental treatments of cloasma and other hypermelanoses","volume":"25","author":"Picardo","year":"2007","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0300","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3389\/fphys.2018.00911","article-title":"Ascorbic acid chemosensitizes colorectal cancer cells and synergistically inhibits tumor growth","volume":"9","author":"Pires","year":"2018","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.ijwd.2018.09.004_bb0305","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jid.2017.07.833","article-title":"Melanocytes sense blue light and regulate pigmentation through the Opsin3","volume":"138","author":"Regazzetti","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2018.09.004_bb0310","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40257-013-0038-4","article-title":"Treatment of melasma with topical agents, peels and lasers: An evidence-based review","volume":"14","author":"Rivas","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0315","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/ajd.12290","article-title":"Melasma: Clinical diagnosis and management options","volume":"56","author":"Rodrigues","year":"2015","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0320","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0923-1811(01)00133-5","article-title":"The effects of the melatonin on ultraviolet-B irradiation cultured dermal fibroblasts","volume":"27","author":"Ryoo","year":"2001","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb9500","first-page":"451","article-title":"Chemical peels for melasma","volume":"26","author":"Sarkar","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"10.1016\/j.ijwd.2018.09.004_bb0325","first-page":"53","article-title":"Melasma in men: A review of clinical, etiological, and management issues","volume":"11","author":"Sarkar","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2018.09.004_bb0330","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4103\/idoj.IDOJ_187_17","article-title":"Evidence-based review, grade of recommendation, and suggested treatment recommendations for melasma","volume":"8","author":"Sarma","year":"2017","journal-title":"Indian Dermatol Online J"},{"issue":"9","key":"10.1016\/j.ijwd.2018.09.004_bb0335","first-page":"964","article-title":"Azelaic acid: Evidence-based update on mechanism of action and clinical application","volume":"14","author":"Schulte","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0340","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/15569527.2013.834496","article-title":"Oxidative stress status in patients with melasma","volume":"33","author":"Se\u00e7kin","year":"2014","journal-title":"Cutan Ocul Toxicol"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0345","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0781.2008.00352.x","article-title":"Polypodium leucotomos inhibits ultraviolet B radiation-induced immunosuppression","volume":"24","author":"Siscovick","year":"2008","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0350","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/0378-6323.179088","article-title":"Glutathione as a skin whitening agent: Fact, myths, evidence and controversies","volume":"82","author":"Sonthalia","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0355","first-page":"30(3)","article-title":"Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies","author":"Taraz","year":"2017","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.ijwd.2018.09.004_bb0360","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/09546630903341945","article-title":"Hydroquinone for skin lightening: Safety profile, duration of use and when should we stop?","volume":"21","author":"Tse","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0365","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1473-2165.2012.00613.x","article-title":"Melasma in men","volume":"11","author":"Vachiramon","year":"2012","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb9600","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1590\/S0365-05962013000100009","article-title":"Mechanisms regulating melanogenesis","volume":"88","author":"Videira","year":"2013","journal-title":"An. Bras. Dermatol"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0370","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jchromb.2017.05.026","article-title":"Inter-laboratory skin distribution study of 4-n-butyl resorcinol: The importance of liquid chromatography\/mass spectrometry (HPLC-MS\/MS) bioanalytical validation","volume":"1060","author":"Wargniez","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ijwd.2018.09.004_bb0375","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/CCID.S68424","article-title":"Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: A double-blind and placebo-controlled clinical trial in healthy women","volume":"7","author":"Watanabe","year":"2014","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2018.09.004_bb0380","first-page":"424","article-title":"Prevalence of self-diagnosed melasma among premenopausal Latino women in Dallas and Fort Worth","volume":"143","author":"Werlinger","year":"2007","journal-title":"Tex Arch Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2018.09.004_bb0385","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000359974","article-title":"Niacinamide - Mechanisms of action and its topical use in dermatology","volume":"27","author":"Wohlrab","year":"2014","journal-title":"Skin Pharmacol Physiol"},{"issue":"4","key":"10.1016\/j.ijwd.2018.09.004_bb0390","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00266-012-9899-9","article-title":"Treatment of melasma with oral administration of tranexamic acid","volume":"36","author":"Wu","year":"2012","journal-title":"Aesthet Plast Surg"}],"container-title":["International Journal of Women's Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647518300431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647518300431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T14:27:13Z","timestamp":1641565633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352647518300431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2352647518300431"],"URL":"https:\/\/doi.org\/10.1016\/j.ijwd.2018.09.004","relation":{},"ISSN":["2352-6475"],"issn-type":[{"value":"2352-6475","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New oral and topical approaches for the treatment of melasma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Women's Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijwd.2018.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of Women's Dermatologic Society.","name":"copyright","label":"Copyright"}]}}